TRIAL DETAIL

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Drug:
Trial Name:
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 04/01/2010
Age of Trial (yrs) 12.4
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor + MEK inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CBKM120B2101, 2009-017157-35
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals +1(800)340-6843
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Inclusion Criteria:

histologically/ cytologically confirmed, advanced non resectable solid tumors
Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
10945 Le Conte Ave.
Los Angeles
CA
90095
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA
610 University Ave
Toronto
ON
M5G 2M9
Canada
Herestraat 49
Leuven
Belgium
119-129
Barcelona
08035
Spain
Bellinzona
Switzerland
Sevilla
Andalucia
41013
Spain